Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.9
USD
|
-4.52%
|
|
-2.56%
|
-36.45%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,630
|
724.8
|
306.1
|
459
|
340
|
359.9
|
-
|
-
|
Enterprise Value (EV)
1 |
1,561
|
775.8
|
612.5
|
837.8
|
257.8
|
359.9
|
359.9
|
359.9
|
P/E ratio
|
-16.6
x
|
-4.97
x
|
-0.54
x
|
-1.77
x
|
-1.47
x
|
-4.71
x
|
10.2
x
|
1.71
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
11
x
|
3.19
x
|
3.9
x
|
6.08
x
|
2.92
x
|
1.36
x
|
0.89
x
|
0.55
x
|
EV / Revenue
|
11
x
|
3.19
x
|
3.9
x
|
6.08
x
|
2.92
x
|
1.36
x
|
0.89
x
|
0.55
x
|
EV / EBITDA
|
-17.6
x
|
-6
x
|
-1.35
x
|
-2.56
x
|
-2.19
x
|
-3.8
x
|
0.99
x
|
1.04
x
|
EV / FCF
|
-22.9
x
|
-8.42
x
|
-1.16
x
|
-2.63
x
|
-2.51
x
|
2.9
x
|
2.08
x
|
-
|
FCF Yield
|
-4.38%
|
-11.9%
|
-86.2%
|
-38.1%
|
-39.8%
|
34.5%
|
48.1%
|
-
|
Price to Book
|
82.1
x
|
-7.01
x
|
-1.6
x
|
-1.28
x
|
-0.68
x
|
-0.9
x
|
-1.04
x
|
-1.19
x
|
Nbr of stocks (in thousands)
|
27,327
|
27,877
|
61,220
|
73,684
|
113,718
|
189,401
|
-
|
-
|
Reference price
2 |
59.63
|
26.00
|
5.000
|
6.230
|
2.990
|
1.900
|
1.900
|
1.900
|
Announcement Date
|
2/27/20
|
2/23/21
|
2/22/22
|
2/21/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
148.4
|
227.5
|
78.45
|
75.48
|
116.3
|
265.2
|
405.6
|
659.2
|
EBITDA
1 |
-92.78
|
-120.8
|
-226.1
|
-179
|
-155.4
|
-94.7
|
363.4
|
345.6
|
EBIT
1 |
-93.1
|
-121.4
|
-226.7
|
-179.5
|
-155.6
|
-16.44
|
105.8
|
285.1
|
Operating Margin
|
-62.75%
|
-53.35%
|
-289.02%
|
-237.83%
|
-133.72%
|
-6.2%
|
26.08%
|
43.25%
|
Earnings before Tax (EBT)
1 |
-97.16
|
-143.6
|
-269.1
|
-233.7
|
-209.2
|
-67.13
|
108.9
|
374.2
|
Net income
1 |
-97.16
|
-143.6
|
-269.1
|
-233.7
|
-209.2
|
-69.55
|
60.42
|
255.8
|
Net margin
|
-65.49%
|
-63.09%
|
-343.04%
|
-309.58%
|
-179.87%
|
-26.23%
|
14.9%
|
38.8%
|
EPS
2 |
-3.590
|
-5.230
|
-9.310
|
-3.520
|
-2.030
|
-0.4038
|
0.1855
|
1.113
|
Free Cash Flow
1 |
-71.29
|
-86.05
|
-263.8
|
-174.8
|
-135.5
|
124
|
173
|
-
|
FCF margin
|
-48.05%
|
-37.81%
|
-336.29%
|
-231.64%
|
-116.46%
|
46.76%
|
42.65%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
47.61%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
286.31%
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/23/21
|
2/22/22
|
2/21/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
14.41
|
15.4
|
18.84
|
18.84
|
18.98
|
18.82
|
24.33
|
25.79
|
50.12
|
33.97
|
32.25
|
84.51
|
42.53
|
68.46
|
69.8
|
79
|
EBITDA
1 |
-55.59
|
-55.48
|
-42.84
|
-52.23
|
-41.52
|
-42.42
|
-48.52
|
-37.01
|
-
|
-27.51
|
-42.36
|
-39.5
|
-34.3
|
-16.3
|
-4.6
|
-
|
EBIT
1 |
-55.74
|
-55.63
|
-42.99
|
-52.38
|
-41.62
|
-42.51
|
-48.6
|
-37.06
|
-
|
-27.53
|
-42.37
|
31.67
|
-23.97
|
-5.092
|
-12.63
|
12.4
|
Operating Margin
|
-386.88%
|
-361.2%
|
-228.23%
|
-277.99%
|
-219.3%
|
-225.92%
|
-199.78%
|
-143.71%
|
-
|
-81.05%
|
-131.37%
|
37.48%
|
-56.36%
|
-7.44%
|
-18.09%
|
15.7%
|
Earnings before Tax (EBT)
1 |
-69.39
|
-65.12
|
-56.73
|
-66.32
|
-55.12
|
-55.49
|
-61.72
|
-49.94
|
-
|
-41.25
|
-56.34
|
5.2
|
-39.22
|
-16.22
|
-18.1
|
-2.5
|
Net income
1 |
-69.39
|
-65.12
|
-56.73
|
-66.32
|
-55.12
|
-55.49
|
-61.72
|
-49.94
|
-
|
-41.25
|
-56.34
|
7.466
|
-38.24
|
-19.41
|
-23.91
|
-2.5
|
Net margin
|
-481.55%
|
-422.82%
|
-301.18%
|
-352.02%
|
-290.4%
|
-294.86%
|
-253.68%
|
-193.65%
|
-
|
-121.43%
|
-174.71%
|
8.83%
|
-89.92%
|
-28.36%
|
-34.25%
|
-3.16%
|
EPS
2 |
-2.620
|
-1.770
|
-0.9300
|
-1.050
|
-0.8100
|
-0.7600
|
-0.7900
|
-0.4600
|
-
|
-0.3700
|
-0.5000
|
0.0494
|
-0.2061
|
-0.1024
|
-0.1332
|
-0.0100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/2/21
|
2/22/22
|
5/3/22
|
8/2/22
|
11/1/22
|
2/21/23
|
5/9/23
|
8/1/23
|
8/1/23
|
11/7/23
|
2/27/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
51
|
306
|
379
|
-
|
-
|
-
|
-
|
Net Cash position
|
68.2
|
-
|
-
|
-
|
82.2
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-0.4221
x
|
-1.355
x
|
-2.116
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-71.3
|
-86
|
-264
|
-175
|
-135
|
124
|
173
|
-
|
ROE (net income / shareholders' equity)
|
-196%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-54.3%
|
-50.6%
|
-73.2%
|
-74.2%
|
-92.2%
|
-11.6%
|
4.75%
|
4.22%
|
Assets
1 |
178.9
|
283.9
|
367.4
|
314.8
|
226.9
|
598.1
|
1,272
|
6,055
|
Book Value Per Share
2 |
0.7300
|
-3.710
|
-3.130
|
-4.880
|
-4.410
|
-2.110
|
-1.820
|
-1.600
|
Cash Flow per Share
2 |
-
|
-3.100
|
-9.130
|
-2.630
|
-1.310
|
0.3400
|
-0.2200
|
-
|
Capex
|
0.95
|
0.87
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
0.64%
|
0.38%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/23/21
|
2/22/22
|
2/21/23
|
2/27/24
|
-
|
-
|
-
|
Average target price
7.414
USD Spread / Average Target +290.23% Consensus |
1st Jan change
|
Capi.
|
---|
| -36.45% | 360M | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|